Patents by Inventor Robert Michael Borzilleri

Robert Michael Borzilleri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolotriazine inhibitors of kinases
    Patent number: 7244733
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: July 17, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John T. Hunt, Rajeev S. Bhide, Robert Michael Borzilleri, Ligang Qian
  • Pyrrolotriazine inhibitors of kinases
    Patent number: 7112675
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: September 26, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: John T. Hunt, Rajeev S. Bhide, Robert Michael Borzilleri, Ligang Qian
  • Pyrrolotriazine inhibitors of kinases
    Patent number: 6982265
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: January 3, 2006
    Assignee: Bristol Myers Squibb Company
    Inventors: John T. Hunt, Rajeev S. Bhide, Robert Michael Borzilleri, Ligang Qian